Loading...
Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.
Na minha lista:
| Udgivet i: | Clin Case Rep |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7069848/ https://ncbi.nlm.nih.gov/pubmed/32185037 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.2688 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|